Genentech Muscle Drug Failure Highlights Limitations of Antibody Approach — and the Case for Imitex
Melbourne, Australia — 21 March 2026
Genentech announced today that its anti-myostatin antibody emugrobart has failed to deliver consistent improvements in muscle growth in clinical trials for two rare muscle wasting diseases — spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD) — and will not advance to Phase 3 development in either indication.
The news raises significant questions about the antibody's continued development in Genentech's ongoing obesity trials, where emugrobart is being tested in combination with Eli Lilly's tirzepatide to preserve muscle mass lost during GLP-1 therapy.
"This outcome is disappointing for patients with SMA and FSHD, and we acknowledge the significant effort that went into these trials," said Dr James Campbell, CEO of Imitex. "But it also reinforces something we have long believed — that blocking a single protein in the muscle growth pathway is an incomplete solution. Muscle health is not governed by one switch."
Imitex is developing a fundamentally different approach. Rather than targeting myostatin — a brake on muscle growth — Imitex's MEF2 activator platform targets the master transcriptional regulator of the cellular response to exercise itself. MEF2 coordinates a broad programme of gene expression that drives muscle adaptation, metabolism and resilience. Activating MEF2 replicates the molecular signature of exercise across multiple pathways simultaneously, rather than modulating a single target.
"The GLP-1 muscle loss problem is real, urgent, and as yet unsolved," said Dr Campbell. "With hundreds of millions of people now on GLP-1 therapies globally, the need for an effective muscle preservation solution has never been greater. We believe that MEF2 activation — replicating what exercise actually does at the molecular level — is the right answer, and this week's news makes that case more compelling."